Purpose: This randomized controlled trial (RCT) protocol was designed to evaluate the effectiveness of the Cancer Pain Monitoring System (CAPAMOS), a telenursing system designed to alleviate pain in ambulatory patient...Purpose: This randomized controlled trial (RCT) protocol was designed to evaluate the effectiveness of the Cancer Pain Monitoring System (CAPAMOS), a telenursing system designed to alleviate pain in ambulatory patients with advanced cancer. Methods: The study design involved a randomized controlled trial consisting of an intervention group using CAPAMOS and a control group that received usual care. At the time of enrollment, both groups will be given a questionnaire regarding issues, such as concerns related to cancer pain and self-management of opioid medication. Patients will then receive pain relief education based on the results of the questionnaire. Subjects in the control group will receive a pain diary and pain-relief pamphlet that acts as an educational tool. They could also call the outpatient clinic if they wanted to ask for a nursing consultation. The intervention group will be able to use CAPAMOS to manage their pain and receive video consultation with a telenurse, who is an oncology nursing specialist. Educational tools will be built into CAPAMOS. The study will be conducted for one month. The primary endpoint of this study was to calculate the Japanese Brief Pain Inventory score. The secondary endpoints were to assess the opioid medication self-management, Barriers Questionnaire, Japanese EuroQol 5-dimensions 5-level, and economic evaluation. Assessment items will be evaluated at registration and 2 and 4 weeks after registration. Conclusions: A RCT based on this protocol is expected to validate the efficacy of telenursing using CAPAMOS in patients with advanced cancer and pain.展开更多
目的探讨舒芬太尼静脉自控镇痛对宫颈癌术后患者疼痛及应激反应的影响。方法选取2020年2月至2022年3月济南市第二妇幼保健院共102例宫颈癌手术患者为研究对象,根据不同麻醉药物分成两组,对照组予地佐辛,研究组予舒芬太尼,均行静脉自控镇...目的探讨舒芬太尼静脉自控镇痛对宫颈癌术后患者疼痛及应激反应的影响。方法选取2020年2月至2022年3月济南市第二妇幼保健院共102例宫颈癌手术患者为研究对象,根据不同麻醉药物分成两组,对照组予地佐辛,研究组予舒芬太尼,均行静脉自控镇痛,比较围术期两组应激反应和炎症因子,疼痛评分,不良反应和镇痛按压次数、抑郁评分变化。结果麻醉前两组应激指标去甲肾上腺素(NE)、肾上腺素(E)、皮质醇(Cor)和炎症因子C反应蛋白(CRP)、肿瘤坏死因子⁃α(TNF⁃α)含量比较差异无统计学意义(P>0.05),术后舒芬太尼组2、6、12、24h指标含量均较同时间段地佐辛组低,差异有统计学意义(P<0.05)。麻醉前和术后2、6、12、24 h两组NRS评分比较差异无统计学意义(P>0.05);麻醉前两组VAS评分比较差异无统计学意义(P>0.05),术后舒芬太尼组6、12、24 h VAS评分均较同时间段地佐辛组低,差异有统计学意义(t=0.971、4.205、14.446、15.345,P<0.05)。舒芬太尼组不良反应发生率显著低于地佐辛组,差异有统计学意义(χ^(2)=4.320,P<0.05),舒芬太尼组镇痛按压次数、抑郁评分显著低于地佐辛组,差异有统计学意义(t=9.579、10.164,P<0.05)。结论舒芬太尼静脉自控镇痛能缓解宫颈癌术后患者疼痛程度,降低机体应激反应,这可能和该药物能抑制炎症反应有关,且不良反应轻。展开更多
OBJECTIVE: To evaluate the safety and efficacy of Tongkuaixiao ointment(TKXO) in treating moderate-to-severe cancer induced somatalgia.METHODS: Totally 130 patients with moderateto-severe cancer induced somatalgia wer...OBJECTIVE: To evaluate the safety and efficacy of Tongkuaixiao ointment(TKXO) in treating moderate-to-severe cancer induced somatalgia.METHODS: Totally 130 patients with moderateto-severe cancer induced somatalgia were randomly divided into a TKXO group and a control group.The patients were treated with either TKXO applied externally or placebo, with opioid analgesics orally at the same time. Observation parameters were included numerical rating scale(NRS) scores,analgesic efficacy, initiation effective time, persistent analgesic time, equivalent morphine dose,National Comprehensive Cancer Network(NCCN)grade in Impact of Pain Measurement Scores, and safety and satisfaction extent investigation.RESULTS: NRS scores and NCCN grade in Impact of Pain Measurement Scores decreased significantly after 5-days' treatment in the two groups(P <0.0001). Compared to the control group, initiation effective time was significantly shorter(P < 0.05)and persistent analgesic time was significantly longer(P < 0.01), equivalent oral morphine doses of the first day and the whole treatment course were significantly decreased in the TKXO treatment group(P < 0.01 or P < 0.05). No obvious adverse effects were found in the TKXO group.CONCLUSION: TKXO combined with opioid analgesics possesses the advantages of high efficacy,fast action, long persistent action, safety and convenience in use, and it can reduce the dose of opioid.展开更多
文摘Purpose: This randomized controlled trial (RCT) protocol was designed to evaluate the effectiveness of the Cancer Pain Monitoring System (CAPAMOS), a telenursing system designed to alleviate pain in ambulatory patients with advanced cancer. Methods: The study design involved a randomized controlled trial consisting of an intervention group using CAPAMOS and a control group that received usual care. At the time of enrollment, both groups will be given a questionnaire regarding issues, such as concerns related to cancer pain and self-management of opioid medication. Patients will then receive pain relief education based on the results of the questionnaire. Subjects in the control group will receive a pain diary and pain-relief pamphlet that acts as an educational tool. They could also call the outpatient clinic if they wanted to ask for a nursing consultation. The intervention group will be able to use CAPAMOS to manage their pain and receive video consultation with a telenurse, who is an oncology nursing specialist. Educational tools will be built into CAPAMOS. The study will be conducted for one month. The primary endpoint of this study was to calculate the Japanese Brief Pain Inventory score. The secondary endpoints were to assess the opioid medication self-management, Barriers Questionnaire, Japanese EuroQol 5-dimensions 5-level, and economic evaluation. Assessment items will be evaluated at registration and 2 and 4 weeks after registration. Conclusions: A RCT based on this protocol is expected to validate the efficacy of telenursing using CAPAMOS in patients with advanced cancer and pain.
文摘目的探讨舒芬太尼静脉自控镇痛对宫颈癌术后患者疼痛及应激反应的影响。方法选取2020年2月至2022年3月济南市第二妇幼保健院共102例宫颈癌手术患者为研究对象,根据不同麻醉药物分成两组,对照组予地佐辛,研究组予舒芬太尼,均行静脉自控镇痛,比较围术期两组应激反应和炎症因子,疼痛评分,不良反应和镇痛按压次数、抑郁评分变化。结果麻醉前两组应激指标去甲肾上腺素(NE)、肾上腺素(E)、皮质醇(Cor)和炎症因子C反应蛋白(CRP)、肿瘤坏死因子⁃α(TNF⁃α)含量比较差异无统计学意义(P>0.05),术后舒芬太尼组2、6、12、24h指标含量均较同时间段地佐辛组低,差异有统计学意义(P<0.05)。麻醉前和术后2、6、12、24 h两组NRS评分比较差异无统计学意义(P>0.05);麻醉前两组VAS评分比较差异无统计学意义(P>0.05),术后舒芬太尼组6、12、24 h VAS评分均较同时间段地佐辛组低,差异有统计学意义(t=0.971、4.205、14.446、15.345,P<0.05)。舒芬太尼组不良反应发生率显著低于地佐辛组,差异有统计学意义(χ^(2)=4.320,P<0.05),舒芬太尼组镇痛按压次数、抑郁评分显著低于地佐辛组,差异有统计学意义(t=9.579、10.164,P<0.05)。结论舒芬太尼静脉自控镇痛能缓解宫颈癌术后患者疼痛程度,降低机体应激反应,这可能和该药物能抑制炎症反应有关,且不良反应轻。
基金Supported by the Eleventh Five-year National Plan of Sciences and Technology(Clinical Research of Traditional Chinese Medicine External Treatment by Investigating Pathogenesis and Syndrome Differentiation of Cancer Pain,No.2008BAI53B023)Key Project of Beijing Municipal Science and Technology Commission(Standardization of Traditional Chinese Medicine External Treatment in Cancer Induced Pain,Ascites or Pleural Effusion,No.D13110002213004)the Postdoctoral Fund of Sciences(Effects of the Method for Tonifying Kidney to Strengthen the Bone in Treating Bone Cancer Pain,No.2012M510358)
文摘OBJECTIVE: To evaluate the safety and efficacy of Tongkuaixiao ointment(TKXO) in treating moderate-to-severe cancer induced somatalgia.METHODS: Totally 130 patients with moderateto-severe cancer induced somatalgia were randomly divided into a TKXO group and a control group.The patients were treated with either TKXO applied externally or placebo, with opioid analgesics orally at the same time. Observation parameters were included numerical rating scale(NRS) scores,analgesic efficacy, initiation effective time, persistent analgesic time, equivalent morphine dose,National Comprehensive Cancer Network(NCCN)grade in Impact of Pain Measurement Scores, and safety and satisfaction extent investigation.RESULTS: NRS scores and NCCN grade in Impact of Pain Measurement Scores decreased significantly after 5-days' treatment in the two groups(P <0.0001). Compared to the control group, initiation effective time was significantly shorter(P < 0.05)and persistent analgesic time was significantly longer(P < 0.01), equivalent oral morphine doses of the first day and the whole treatment course were significantly decreased in the TKXO treatment group(P < 0.01 or P < 0.05). No obvious adverse effects were found in the TKXO group.CONCLUSION: TKXO combined with opioid analgesics possesses the advantages of high efficacy,fast action, long persistent action, safety and convenience in use, and it can reduce the dose of opioid.
